Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does treatment present material risks?

M J Langman

    Scandinavian Journal of Gastroenterology. Supplement
    |January 1, 1986
    PubMed
    Summary

    Confirming the safety of anti-secretory treatments requires extensive real-world use. Careful data analysis is crucial to distinguish drug effects from pre-existing conditions, especially for medications like cimetidine.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Epidemiology of cancer of the large intestine.

    Proceedings of the Royal Society of Medicine·2010
    Same author

    Postmarketing surveillance of the safety of cimetidine: 15-year mortality report.

    Pharmacoepidemiology and drug safety·2004
    Same author

    Which PPI?

    Gut·2001
    Same author

    Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?

    Pharmacoepidemiology and drug safety·2001
    Same author

    Heparin therapy for ulcerative colitis? Effects and mechanisms.

    European journal of gastroenterology & hepatology·2001
    Same author

    Drug treatment of non-variceal upper gastrointestinal bleeding.

    Bailliere's best practice & research. Clinical gastroenterology·2000

    Area of Science:

    • Pharmacology and Drug Safety
    • Clinical Trial Analysis
    • Gastroenterology

    Background:

    • Extensive use is necessary to confirm the safety of anti-secretory treatments.
    • Animal studies, pharmacological investigations, and controlled trials are preliminary but insufficient alone.
    • Interpreting drug safety is complicated by coincident diseases present before treatment.

    Purpose of the Study:

    • To highlight the challenges in confirming drug safety due to confounding factors.
    • To emphasize the need for careful data analysis in drug safety studies.
    • To review the available data on cimetidine safety as a case study.

    Main Methods:

    • Analysis of data from extensive post-marketing use.
    • Examination of controlled trials and human pharmacological studies.
    • Investigating the impact of coincident diseases on safety data interpretation.

    Main Results:

    • A substantial body of data exists for cimetidine, providing reassurance of its safety in ordinary use.
    • Confounding by coincident disease significantly impedes the demonstration of drug-induced illness.
    • The difficulty in demonstrating drug-induced illness that mimics ordinary disease is confirmed.

    Conclusions:

    • Confirming the safety of anti-secretory drugs requires long-term observational data.
    • Coincident diseases present a major challenge in interpreting drug safety studies.
    • Future drug safety studies must account for confounding factors and employ rigorous data analysis.

    Related Experiment Videos